These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36204505)

  • 1. Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications.
    Tubic B; Marković-Peković V; Jungić S; Allocati E; Godman B
    Med Access Point Care; 2021; 5():23992026211027692. PubMed ID: 36204505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
    Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
    Godman B; Haque M; Leong T; Allocati E; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Vassalo C; Bakar MA; Rahim SA; Sultana N; Deeba F; Khan MAH; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Rwegerera GM; do Nascimento RCRM; Dias Godói IP; Irfan M; Amu AA; Matowa P; Acolatse J; Incoom R; Sefah IA; Acharya J; Opanga S; Njeri LW; Kimonge D; Kwon HY; Bae S; Khuan KKP; Abubakar AR; Sani IH; Khan TA; Hussain S; Saleem Z; Malande OO; Piloya-Were T; Gambogi R; Hernandez Ortiz C; Alutuli L; Kalungia AC; Hoxha I; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Laius O; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuoliene K; Gulbinovič J; Wladysiuk M; Rutkowski J; Mardare I; Fürst J; McTaggart S; MacBride-Stewart S; Pontes C; Zara C; Tagoe ET; Banzi R; Wale J; Jakovljevic M
    Front Public Health; 2021; 9():671961. PubMed ID: 34249838
    [No Abstract]   [Full Text] [Related]  

  • 4. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.
    Godman B; Haque M; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Allocati E; Bakar MA; Rahim SA; Sultana N; Deeba F; Halim Khan MA; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Acharya J; Sugahara T; Kwon HY; Bae S; Khuan KKP; Khan TA; Hussain S; Saleem Z; Pisana A; Wale J; Jakovljevic M
    Curr Med Res Opin; 2021 Sep; 37(9):1529-1545. PubMed ID: 34166174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory aspects of biological medicines in Bosnia and Herzegovina.
    Tubić B; Jungić S
    Bosn J Basic Med Sci; 2022 Jul; 22(4):511-522. PubMed ID: 35460398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications.
    Haque M; Islam S; Kamal ZM; Akter F; Jahan I; Rahim MSA; Sultana N; Alam AM; Munzur-E-Murshid ; Halim-Khan MA; Deeba F; Bakar MA; Nahar S; Mozaffor M; Urmi UL; Saikat TR; Islam MZ; Haque M; Iqbal S; Hossain MM; Naher N; Allocati E; Godman B
    Hosp Pract (1995); 2021 Oct; 49(4):266-272. PubMed ID: 33734004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.
    Moorkens E; Jonker-Exler C; Huys I; Declerck P; Simoens S; Vulto AG
    Front Pharmacol; 2016; 7():193. PubMed ID: 27445826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in Developed Economies: Overview, Status, and Regulatory Considerations.
    Rathore AS; Bhargava A
    Regul Toxicol Pharmacol; 2020 Feb; 110():104525. PubMed ID: 31743691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.
    Chapman SR; Fitzpatrick RW; Aladul MI
    BMJ Open; 2017 Jun; 7(6):e016730. PubMed ID: 28637743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.
    Inotai A; Csanadi M; Petrova G; Dimitrova M; Bochenek T; Tesar T; York K; Fuksa L; Kostyuk A; Lorenzovici L; Omelyanovskiy V; Egyed K; Kalo Z
    Biomed Res Int; 2018; 2018():9597362. PubMed ID: 29546072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
    Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
    Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody biosimilars for cancer treatment.
    Broer LN; Knapen DG; de Groot DA; Mol PGM; Kosterink JGW; de Vries EGE; Lub-de Hooge MN
    iScience; 2024 Jun; 27(6):110115. PubMed ID: 38974466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies.
    Doevendans E; Schellekens H
    Antibodies (Basel); 2019 Mar; 8(1):. PubMed ID: 31544827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.